Core Insights - electroCore, Inc. has announced a new research initiative in collaboration with Acacia Clinics and the Vagus Nerve Society to investigate the use of gammaCore™ Sapphire, a non-invasive vagus nerve stimulator (nVNS), as an adjunctive treatment for PTSD symptoms [1][2] Study Details - The study titled "Non-Invasive Vagus Nerve Stimulation (nVNS) for Adjunctive Treatment of Symptoms Associated with Post-Traumatic Stress Disorder" will be led by Danielle DeSouza MSc, PhD, and aims to assess the safety and effectiveness of gammaCore Sapphire [2] - The primary safety measure will focus on significant adverse events (SAEs) related to nVNS treatment, while the primary efficacy outcome will be the change in the Clinician-Administered PTSD Scale (CAPS-5) total score after a 12-week treatment period [2] - The study will enroll up to 40 subjects aged 18 to 70 diagnosed with PTSD and is expected to last for 10 months [3] Background Information - Acacia Clinics is recognized for its expertise in precision neuromodulation and advanced mental health services, founded in 2018 by Dr. David Carreon and Dr. Nathan Meng [4] - electroCore, Inc. focuses on improving health through innovative non-invasive bioelectronic technologies, with products like gammaCore® and Quell® targeting chronic pain syndromes [5]

Financial Guidance - electroCore, Inc. provided preliminary financial guidance for the three and 12 months ended December 31, 2025[4] - The financial results are based on unaudited information and management estimates, subject to change[6] - The company cautioned that actual results may differ materially from the preliminary estimates provided[8] - Upcoming presentations will include these preliminary financial estimates for investor and analyst discussions[5] Audit and Review - The independent registered public accounting firm has not conducted an audit or review of these preliminary results[6] - The financial information is not deemed "filed" under the Securities Exchange Act of 1934[7] Risk Factors - Investors are advised to refer to the "Risk Factors" section of the Company's Annual Report for potential discrepancies in actual results[8] Forward-Looking Statements - The company has no obligation to publicly release updates on forward-looking statements unless required by law[8] Documentation - The press release and investor presentation are filed as Exhibits 99.1 and 99.2, respectively[11] - The report was signed by Joshua S. Lev, Chief Financial Officer, on January 20, 2026[15]

Core Insights - electroCore, Inc. anticipates record revenue for full year 2025 of approximately $31.8 - $32.0 million, representing a growth of about 26% compared to 2024 revenue of $25.2 million [2][7] - For the fourth quarter of 2025, the company expects revenue to be approximately $9.0 - $9.2 million, indicating a growth of around 30% over the fourth quarter of 2024 [2][7] - The company's total cash position at the end of 2025 is approximately $11.6 million, down from approximately $13.2 million as of September 30, 2025 [3][7] Financial Guidance - Full year 2025 revenue is projected to be between $31.8 million and $32.0 million, marking a 26% increase from 2024 [2][7] - Fourth quarter 2025 revenue is expected to be between $9.0 million and $9.2 million, reflecting a 30% increase from the same quarter in 2024 [2][7] Company Overview - electroCore, Inc. is a bioelectronic technology company focused on improving health and quality of life through non-invasive bioelectronic technologies [4] - The company's leading products include gammaCore non-invasive vagus nerve stimulation (nVNS) and Quell neurostimulator, which address chronic pain syndromes [4]

Company Overview - electroCore is a publicly traded neuromodulation company listed on NASDAQ under the symbol ECOR, focusing on non-invasive vagus nerve stimulation devices [3] - The company was founded in 2006 and has developed into a multi-indication business with 7 FDA authorizations for headache treatments [5] Product and Service Channels - The company operates across three main channels: prescription medical devices for headache and migraine, the Truvaga direct-to-consumer wellness brand, and a specialized military and government division featuring the ruggedized TAC-STIM product [4] - The nVNS platform delivers a two-minute therapy session aimed at rebalancing the autonomic nervous system [3] Market and Clientele - electroCore serves major customers including the U.S. Department of Veterans Affairs and the U.K.'s National Health Service, indicating a strong foothold in both governmental and healthcare sectors [5]

Core Insights - electroCore, Inc. announced the publication of a peer-reviewed paper demonstrating the effectiveness of its TAC-STIM™ device in enhancing mood, task performance, and learning in high-stress military training environments [1][2] Study Findings - The study involved 70 active-duty Air Force trainees, who were randomly assigned to receive either tVNS or a sham device during intensive Military Qualification Training [8] - tVNS users reported significantly reduced stress and distress, greater energy, and perceived skill improvements compared to the control group, with p-values indicating statistical significance (p<0.001 for distress, p=0.020 for perceived ability, p=0.002 for energy) [8] - Objective performance gains were observed in intelligence product quality and mission task execution, with tVNS users excelling in real-time operational scenarios [8] Product Positioning - TAC-STIM is positioned as a neuroenhancement tool specifically designed for defense and security applications, with potential for consumer wellness, workplace productivity, and educational markets [5] - The technology aligns with the growing demand for cognitive augmentation tools in civilian domains, including executive training, sports, and healthcare [5] Company Overview - electroCore, Inc. focuses on improving health and quality of life through innovative non-invasive bioelectronic technologies, with leading products including gammaCore and Quell for chronic pain treatment [6] - The company also commercializes handheld products like Truvaga™ and TAC-STIM for general wellness and human performance [6]

Core Insights - electroCore, Inc. is participating in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum on November 20, 2025, in New York [1] - The company will host one-on-one meetings throughout the day for investors [1][2] Company Overview - electroCore, Inc. is a bioelectronic technology company focused on improving health and quality of life through non-invasive bioelectronic technologies [3] - The company's leading products include gammaCore, a non-invasive vagus nerve stimulation device for chronic pain, and Quell Fibromyalgia [3] - Additionally, electroCore offers handheld products like Truvaga and TAC-STIM, which utilize bioelectronic technologies for general wellness and human performance [3]

Core Points - Ecora Resources PLC announced share acquisitions by its CEO Marc Bishop Lafleche and CFO Kevin Flynn, indicating confidence in the company's future performance [1][2][4]. Summary by Sections Share Acquisitions - On November 4, 2025, CEO Marc Bishop Lafleche acquired 32,000 ordinary shares at an average price of £0.931 per share [2][4]. - On November 5, 2025, CFO Kevin Flynn acquired 21,175 shares at an average price of £0.954 per share [2][5]. Regulatory Compliance - The transactions were reported in accordance with Article 19 of the UK Market Abuse Regulation, ensuring transparency in director dealings [3][4]. Company Information - Ecora Resources PLC is listed on the London Stock Exchange and the Toronto Stock Exchange, with the identification code GB0006449366 for its ordinary shares [4][5].

Core Points - The article discusses the importance of enabling Javascript and cookies in browsers to prevent access issues [1] - It highlights that users with ad-blockers may face restrictions when trying to access content [1] Summary by Categories Technical Requirements - Users are advised to enable Javascript and cookies in their browsers to ensure proper functionality [1] - The presence of ad-blockers can lead to blocked access, necessitating their disabling for full content access [1]

分组1 - electroCore, Inc. reported a quarterly loss of $0.4 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.36, and compared to a loss of $0.31 per share a year ago, indicating an earnings surprise of -11.11% [1] - The company posted revenues of $8.69 million for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 10.69%, and showing an increase from $6.55 million in the same quarter last year [2] - electroCore shares have declined approximately 69.5% since the beginning of the year, contrasting with the S&P 500's gain of 15.1% [3] 分组2 - The current consensus EPS estimate for the upcoming quarter is -$0.26 on revenues of $8.89 million, and for the current fiscal year, it is -$1.59 on revenues of $30.84 million [7] - The Zacks Industry Rank for Medical - Drugs is currently in the top 40% of over 250 Zacks industries, suggesting that the industry outlook can significantly impact stock performance [8]

Financial Data and Key Metrics Changes - In Q3 2025, revenue reached a record $8.7 million, up 33% year over year and 18% sequentially [17] - Gross margins improved to 86%, up from 84% in the previous year [17] - GAAP net loss was $3.4 million, or a loss of $0.40 per share, compared to a net loss of $2.5 million, or a loss of $0.31 per share in Q3 2024 [28] - Cash balance as of September 30, 2025, was approximately $13.2 million, compared to $12.2 million at the end of 2024 [29] Business Line Data and Key Metrics Changes - Prescription device revenue grew 19% year over year to $6.8 million, driven by gammaCore and Quell sales in the VA hospital system [17] - Health and wellness product revenue reached $1.9 million, a 54% increase sequentially and 121% year on year [18] - Truvaga revenue grew 18% sequentially and 79% year on year, excluding a one-time $500,000 order for a clinical trial [19] Market Data and Key Metrics Changes - As of September 30, 2025, 195 VA hospital facilities purchased prescription gammaCore products, up from 166 a year ago [17] - The VA hospital system remains the largest customer, with significant growth opportunities identified in the fibromyalgia patient segment [18] Company Strategy and Development Direction - The company is focusing on three strategic pivots: the Neurometrics acquisition, strengthening the VA channel, and developing the wellness division [9][10][11] - The acquisition of Neurometrics has exceeded revenue expectations and is integrated into the VA hospital channel [23] - The company aims to broaden its product range and diversify revenue streams to enhance long-term shareholder value [9][10] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in prioritizing growth over immediate profitability, with a revised timeline for achieving positive adjusted EBITDA in the second half of 2026 [22] - The company is navigating external macroeconomic challenges while maintaining a focus on expanding its market presence [11][12] Other Important Information - The company is facing a patent infringement dispute with a European company, which is currently in litigation [51] - A royalty-based arrangement has been established for commercialization in China, with no capital investment required from the company [13][43] Q&A Session Summary Question: Can you remind us what channels Neurometrics was selling into before the acquisition? - The prescription Quell for fibromyalgia was sold in four or five VA hospitals off contract through open market access prior to the acquisition [36] Question: Can you give us any further color on the $500,000 Truvaga sale for a clinical trial? - It's one clinical trial being run in long COVID subjects, and details are limited as it is investigator-initiated [36] Question: Talk about the next-gen mobile app that you're working on. - The next update of the app will be Truvaga Plus only and will not be set up to work with gammaCore or Quell [37] Question: What is being done to combat the copycat marketing vagus nerve stimulation devices? - The company is in litigation with a European company for patent infringement and is focusing on winning the case [51] Question: How meaningful is the market opportunity in China? - The Chinese investor plans to commercialize the technology in China as a prescription medical device, with royalties paid to the company [43]